Alterations of striatal glutamate transmission in rotenone-treated mice: MRI/MRS in vivo studies

Experimental Neurology

Volumn 209, Issue 1, 2008, Pages 224-233

  Moussa, Charbel E H ^a   Rusnak, Milan ^a   Hailu, Ayichew ^a   Sidhu, Anita ^a   Fricke, Stanley T ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

1H MRS; Glutamate; In vivo; MRI; Neurodegeneration; Rotenone; Striatum

Indexed keywords

GLUTAMIC ACID; NEUROTRANSMITTER; ROTENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN VENTRICLE; CORPUS STRIATUM; DEGENERATIVE DISEASE; ENERGY TRANSFER; HISTOPATHOLOGY; IN VIVO STUDY; MALE; METABOLIC REGULATION; MOUSE; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; STRIA TERMINALIS; STRIATE CORTEX;

ANIMALS; BRAIN; CELL DEATH; CITRIC ACID CYCLE; ENERGY METABOLISM; FEEDBACK; GLUTAMIC ACID; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED C57BL; NEOSTRIATUM; NEUROTOXICITY SYNDROMES; OXIDATIVE PHOSPHORYLATION; ROTENONE; SYNAPTIC TRANSMISSION; TYROSINE 3-MONOOXYGENASE; UNCOUPLING AGENTS;

EID: 37549000637     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.09.023     Document Type: Article

References (64)

1. Azerberger T., Krampfl K., Leimgruber S., and Weindl A. Changes of NMDA receptor subunit (NR1NR2B) and glutamate transporter (GLT-1) mRNA expression in Huntington's disease-an in situ hybridization study. J. Neuropathol. Exp. Neurol. 56 (1997) 440-454
2. Alam Z.I., and Schmidt W.J. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav. Brain Res. 136 (2002) 914-921
3. Avallone J., Gashi E., Magrys B., and Friedman L.K. Distinct regulation of metabotropic glutamate receptor (mGluR1 alpha) in the developing limbic system following multiple early-life seizures. Exp. Neurol. 202 (2006) 100-111
4. Bradford H.F., and Ward H.K. On glutaminase in mammalian synaptosomes. Brain Res. 110 (1976) 115-125
5. Brujin L.I., Becher M.W., Lee M.K., Anderson K.L., Jenkins N.A., Copeland N.G., Sisodia S.S., Rothstein J.D., Borchelt D.R., Price D.L., and Cleveland D.W. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD-1 containing inclusions. Neuron 18 (1997) 327-328
6. Bertabet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (2000) 1301-1306
7. Curtis D.R., and Watkins J.C. The chemical excitation of spinal neurons by certain amino acids. J. Physiol. (London) 166 (1961) 1-14
8. Curtis D.R., and Johnson G.A.R. Amino acid transmitters in the mammalian central nervous system. Ergebn. Physiol. 69 (1974) 94-188
9. Cepeda C., Andre V.M., Levine M.S., Salamon N., Miyata H., Vinters H.V., and Mathern G.W. Epileptogenesis in pediatric cortical displasia: the dysmature cerebral developmental hypothesis. Epilepsy Behav. 9 2 (2006) 219-235
10. Cowan C.M., and Raymond L.A. Selective neuronal degeneration in Huntington's disease. Curr. Top. Dev. Boil. 75 (2006) 25-41
11. Danbolt, N.C. 2000. Sodium- and potassium-dependent amino acid transporters in brain plasma membrane. Pages 231-254, in Bjorklund, A., and Hokfelt, T. (series Eds). Handbook of chemical neuroanatomy. Vol 18, Ottersen, O.P. and Strom-Mathisen, J. (Eds). Glutamate. Elsevier, Amesterdam, Lausanne, New York, Oxford Shannon, Singapore, Tokyo.
12. Danbolt N.C. Glutamate uptake (review). Prog. Neurobiol. 65 (2001) 1-105
13. Fonnum F. Glutamate: a neurotransmitter in the mammalian brain (review). J. Neuroschemistry 42 1 (1984) 1-11
14. Fall P.A., Fredrikson M., Axelson O., and Granerus A.K. Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. Mov. Disord. 14 (1999) 28-37
15. Fricke S.T., et al. Consistent and reproducible slice selection in rodent brain using a novel stereotaxic device for MRI. J. Neurosci. Methods 136 1 (2004) 99-102
16. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., and Richardson R.J. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50 (1998) 1346-1350
17. Greenamyre J.T., MacKenzie G., Peng T.I., and Stephans S.E. Mitochondrial dysfunction in Parkinson's disease. Biochem. Soc. Symp. 66 (1999) 85-97
18. Greenamyre J.T., Sherer T.B., Betarbet R., and Panov A.V. Complex I and Parkinson's disease. IUBMB Life 52 (2001) 135-141
19. Gao H.M., Hong J.S., Zhang W., and Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci. 22 (2002) 782-790
20. Gao H.M., liu B., and Hong J.S. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci. 23 (2003) 6181-6187
21. Gubellini P., Eusebio A., Oueslati A., Melon C., Kerkerian-Le Goff L., and Salin P. Chronic high frequency stimulation of the sub-thalamic nucleus and L-DOPA treatment in experimental parkinsonism; effects of motor behaviour and striatal glutamate transmission. Eur. J. Neuro. Sci. 24 (2006) 1802-1814
22. Hamberger A., Berthold C.H., Karlsson B., Lehmann A., and Nystrom B. Extracellular GABA, glutamate, and glutamine in vivo-perfusion dialysis of rabbit hippocampus. Neurol. Neurobiol. 7 (1983) 473-492
23. Hamberger A., and Nystrom B. Extra- and intracellular amino acids in the hippocampus during development of hepatic encephalopathy. Neurochem. Res. 9 (1984) 1181-1192
24. Hatefi Y. The mitochondrial electron transport and oxidative phosphorylation system. Ann. Rev. Biochem. 54 (1985) 1015-1069
25. Higgins Jr. D.S., and Greenamyre J.T. [3]Dihydrorotenone binding to NADH;ubiquitinone reductase (complex I) of the electron transfer chain: an autoradiographic study. J. Neurosci. 16 (1996) 3807-3816
26. Hoglinger G.U., Feger J., Prigent A., Michel P.P., Parain K., Champy P., Ruberg M., Oertel W.H., and Hirsch E.C. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J. Neurochem. 84 (2003) 491-502
27. Hayashi T., Shoji M., and Abe K. Molecular mechanisms of ischemic neuronal cell death with relevance to Alzheimer's disease. Curr. Alzheimer Res. 3 (2006) 351-358
28. Kweon G.R., Marks J.D., Krencik R., Leung E.H., Schumacker P.T., Hyland K., and Kang U.J. Distinct mechanisms of neurodegeneration induced by complex I inhibition in dopaminergic and non-dopaminergic cells. J. Boil. Chem. 279 50 (2004) 51783-51792
29. Kirvell S.L., Esiri M., and Francis P.T. Down-regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer's disease. J. Neurochem. 98 (2006) 939-950
30. Lehre K.P., Levy L.M., Otterson O.P., Strom-Mathisen J., and Danbolt N.C. Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations. J. Neurosci. 15 (1995) 1835-1853
31. Li S., Mallory M., Alford M., Tanaka S., and Masliah E. Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J. Neuropathol. Exp. Neurol. 56 (1997) 901-911
32. Liou H.H., Tsai M.C., Chen C.J., Jeng J.S., Chang Y.C., Chen S.Y., and Chen R.C. Environmental risk-factors and Parkinson's disease: a case-control study in Taiwan. Neurology 48 (1997) 1583-1588
33. Lin C.L., Bristol L.A., Jin L., Dykes-Hoberg M., Crawford T., Clawson L., and Rothstein J.D. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 20 (1998) 589-602
34. Lievens J.C., Woodman B., Mahal A., Spasic-Boscovic O., Samuel D., Kerkerian-Le Goff L., and Bates G.P. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol. Dis. 8 (2001) 807-821
35. Leng A., Feldon J., and Ferger B. Rotenone increases glutamate-induced dopamine release but does not affect hydroxyl-free radical formation in rat striatum. Synapse 50 (2003) 240-250
36. Lapointe N., St Hilaire M., Martinoli M.G., Blanchet J., Gould P., Rouillard C., and Cicchetti F. Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J. 18 (2004) 117-119
37. Morano A., Jimenez-Jimenez F.J., Molina J.A., and Antolin M.A. Risk-factors for Parkinson's disease: case-control study in the province of Caceres, Spain. Acta Neurol. Scand. 89 (1994) 164-170
38. Masliah E., Alford M., De Teresa R., Mallory M., and Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann. Neurol. 40 (1996) 759-766
39. Marder k., Logroscino G., Alfaro B., Mejia H., Halim A., Louis E., Cote L., and Mayeux R. Environmental risk factors for Parkinson's disease in an urban multiethnic community. Neurology 50 (1998) 279-281
40. Moussa E.-H.C., Mitrovic A.D., Vandenberg R.J., Provis T., Rae C., Bubb W.A., and Balcar V.J. Effects of l-glutamate transport inhibition by a conformationally restricted glutamate analogue (2S, 1′S, 2′S)-2-(carboxycyclopropyl)glycine (L-CCGIII) on metabolism in brain tissue in vitro analyzed by NMR spectroscopy. Neurochem. Res. 27 (2002) 27-35
41. Moussa E.-H.C., Rae C., Bubb W.A., Griffin J.L., Deters N.A., and Balcar V.J. Inhibitors of glutamate transport modulate distinct patterns in brain metabolism. J. Neurosci. Res. 85 (2007) 342-350
42. Oechmichen M., and Meissner C. Cerebral hypoxia and ischemia: the forensic point of view: a review. J. Forensic Sci. 51 (2006) 880-887
43. Perier C., Bove J., Vila M., and Przedborski S. The rotenone model of Parkinson's disease. Trends Neurosci. 26 (2003) 345-346
44. Reijnierse G.L.A., Veldstra H., and Van den Berg C.J. Subcellular localization of gamma-aminobutyric transaminase and glutamate dehydrogenase in adult rat brain. J. Neurochem. 152 (1975) 469-475
45. Roberts P.J., Storm-Mathesin J., and Johnson G.A.R. Glutamate Transmitter in the Central Nervous System (1981), John Wiley and Sons, Chichester
46. Rothstein J.D., Van Kammen M., Levey A.I., Martin L.J., and kuncl R.W. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. 38 (1995) 73-84
47. Rae C., Moussa E.-H.C., Griffin J.L., Bubb W.A., Wallis T., and Balcar V.J. Group I and II metabotropic glutamate receptors alter brain cortical metabolic and glutamate/glutamine cycle activity: a 13C NMR spectroscopy and metabolomic study. J. Neurochem. 92 (2005) 405-4016
48. Rae C., Moussa E.-H.C., Griffin J.L., Parekh S.B., Bubb W.A., Hunt N.H., and Balcar V.J. A metabolomic approach to ionotropic glutamate receptor subtype function: a nuclear magnetic resonance in vitro investigation. J. Cereb. Blood Flow Metab. 26 (2006) 1005-1017
49. Semchuk K.M., Love E.J., and Lee R.G. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 42 (1992) 1328-1335
50. Semchuk K.M., Love E.J., and Lee R.G. Parkinson's disease: a test of the mutlifactorial etiologic hypothesis. Neurology 43 (1993) 1173-1180
51. Schmitt A., Asan E., Puschel B., Jons T., and Kugler P. Expression of the glutamate transporter GLT1 in neuronal cells of the rat central nervous system: non-radioactive in situ hybridization and comparative immunohistochemistry. Neurosci. 71 (1996) 789-1004
52. Schuler F., and Casida J.E. Functional coupling of PSST and ND1 subunits in NADH;ubiquitinone oxireductase established by photoaffinity labeling. Biochem. Biophys. Acta 1506 (2001) 79-87
53. Scott H.L., Pow D.V., Tannenberg A.E., and Dodd P.R. Aberrant expression of the glutamate transporter excitatory amino acid transporter 1 (EAAT1) in Alzheimer's disease. J. Neurosci. 22 (2002) RC206
54. Sherer T.B., Betarbet R., Kim J.H., and Greenamyre J.T. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci. Lett. 341 (2003) 87-90
55. Sherer T.B., Betarbet R., Tesla C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., and Greenamyre J.T. Mechanisms of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23 (2003) 10756-10764
56. Sherer T.B., Kim J.H., Betarbet R., and Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 179 (2003) 9-16
57. Trotti D., Rolfs A., Danbolt N.C., Brown Jr. R.H., and Hediger M.A. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat. Neurosci. 2 (1999) 427-433
58. Talpade D.J., Greene J.G., Higgins Jr. D.S., and Greenamyre J.T. In vivo labeling of mitochondrial complex I (NADH:ubiquitinone oxireductase) in rat brain using [(3)]dihydrorotenone. J. Neurochem. 75 (2000) 2611-2621
59. Uversky N.V. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res. (2004) 441-476
60. Van den Berg C.J., and Garfinkel D. A stimulation study of brain compartments-metabolism of glutamate and related substances in mouse brain. J. Biochem. 123 (1971) 211-218
61. Vanacore N., Nappo A., Gentile M., Brustolin A., Palange S., Liberati A., Di Rezze S., Caldora G., Gasparini M., Benedetti F., Bonifati V., Forastiere F., Quercia A., and Meco G. Evaluation risk of Parkinson's disease in a cohort licensed pesticide users. Neurol. Sci. suppl 2 (2002) S119-S120
62. Van Landeghem F.K., Weiss T., Oechmichen M., and von Deimling A. Decreased expression of glutamate transporters in astrocytes after human traumatic brain injury. J. Neurotrauma 23 (2006) 1518-1528
63. Van Damme P., Dewil M., Robberecht W., and Van Den Bosch L. Excitotoxicity and amyotrophic lateral sclerosis. Neurodgener. Dis. 2 (2005) 147-159
64. Yushkevich P.A., Piven J., Hazlett H.C., Smith R.G., Ho S., Gee J.C., and Gerig G. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage 31 3 (2006) 1116-1128